Method of autoimmunity correction in ischemic heart disease

Abstract

The influence of a new enterosorbent-enterosgel on the immune and autoimmune process in the dynamics of ischemic heart disease and the possibilities of endogenic intoxication decrease using the given drug are estimated. The use of enterosgel made it possible to get the high therapeutic hypolipidemic and autoimmunocorrecting effect in patients with ischemic heart disease, expressed in the improvement of the state - the decrease of the frequency of stenocardia making it case of peace and effort making it possible to decrease daily nitroglycerine dose.